Ara
Toplam kayıt 4, listelenen: 1-4
The Impact Of Jak1/Jak2 Inhibitor Ruxolitinib On The Spleen Size And Symptom Burden In Myeloproliferative Diseases
(Akad Doktorlar Yayınevi, 2016)
Ruxolitinib as a JAK1 and JAK2 inhibitor drug has recently been approved for the treatment of patients with high-or intermediate-risk myelofibrosis with symptomatic splenomegaly. Clinical development of ruxolitinib has ...
The Impact Of Iron Overload On Transplant-Related Complications And Prognosis Of Acute Leukemias
(Akad Doktorlar Yayınevi, 2016)
The impacts of serum iron parameters and/or radiological evidence of systemic iron overload on the prognosis of hematopoietic stem cell transplantation (HSCT) in acute leukemia are controversial. Unfortunately, some of the ...
Idelalisib At The Crossroads Of B-Cell Lymphoproliferative Disorders
(Akad Doktorlar Yayınevi, 2016)
Phosphatidylinositol 3-kinases (PI3Ks) are considered as lipid kinases that are very active in the pathobiology of lymphoproliferative disorders (LPDs). Idelalisib, a selective inhibitor of the delta isoform of PI3K, ...
Molecular Management Of Chronic Lymphocytic Leukemia: Towards A Chemotherapy-Free Approach
(Akad Doktorlar Yayınevi, 2016)
B-cell receptor (BCR) signaling is implicated as a pivotal pathway in tumorigenesis in B-cell malignancies. The inhibitors of Bruton's tyrosine kinase (BTK) and phosphatidylinositide 3-kinase-delta (PI3K), modulating BCR ...